Texas Society of Clinical Oncology

During a live event, Tian Zhang, MD, MHS, discussed darolutamide in mHSPC, with efficacy and cost being key considerations for treatment selection.

During a live event, Tian Zhang, MD, MHS, discussed options and recent trial data for treating metastatic hormone-sensitive prostate cancer.

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed trials of targeted agents for EGFR-mutant lung cancer.

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Hatim Husain, MD, explained the significance of the PACIFIC trial and its real-world counterpart PACIFIC-R looking at the use of durvalumab after chemotherapy and radiation in patients with unresectable stage III non–small cell lung cancer.

In the first of a 2-part article series, Kartik Konduri, MD, discusses the data behind the use of adagrasib and sotorasib for patients with advanced non–small cell lung cancer harboring a KRAS G12C mutation.

During a Targeted Oncology™ Clinical Case Forum™ event, Terry P. Mamounas, MD, MPH, discussed the treatment landscape for patients with HER2-positive breast cancer.

Kartik Konduri, MD discussed treatment options for extensive-stage small cell lung cancer during a live virtual event.

This 2-day CME-event will review the latest advances in lung cancer focused on what a medical oncologist needs to know to provide state-of-the-art care today.